Podcast appearances and mentions of Mark E Robson

In honor of Breast Cancer Awareness Month, today's episode highlights Rachel Silver-Cohen's special friend and real-life superhero, Stephanie Robin. Stephanie meets the gals on the corner of Audacity & Advice to share her courageous story; first battling Stage II Breast Cancer and then having to tackle a Stage IV diagnosis after her cancer metastasized to both lungs. Initially under the pristine care of Dr. Louise Morrell, Medical Oncology Specialist in Boca Raton, Florida she quickly learned the necessity of knowing family history as it relates to the BRCA1 & BRCA2 genes and the risks associated with these mutations. Subsequently, Dr. Mark E. Robson, Associate Attending Physician of the Clinical Genetics & Breast Medicine Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City invited Stephanie to join his clinical trial. Fourteen years later, Stephanie is N.E.D. "No Evidence of Disease!" To this day, Stephanie maintains her mantra, "Pink Is Not Just A Color, It's An Attitude." As creator and founder of Think Pink Rocks, a non-profit organization whose mission is to raise awareness about early detection of and genetic testing for breast cancer and to provide funding for screening, treatment and research, Stephanie is a Survivor, a Warrior and a Real Life Superhero who continues to advocate for awareness helping both men and women in an effort to save lives. She not only walks the walk daily, but today she candidly talks the talk about her personal journey and what life feels like beyond beating Metastatic Breast Cancer. If you're looking to hear a success story, this is an episode you won't want to miss! For More Information on Think Pink Rocks or to contact Stephanie with questions or concerns, please visit www.ThinkPinkRocks.org Follow Think Pink Rocks on Instagram @ThinkPinkRocks Have Additional Comments? Questions? Concerns? Email Us: UnpolishedTherapy@gmail.com Find Us On Facebook & Instagram @UnpolishedTherapy and on Twitter @UnTherapy Donations to Think Pink Rocks will benefit 501(c)(3) charitable organizations and will be contributed to the dedicated Think Pink Rocks Breast Cancer Research Funds at each of Memorial Sloan Kettering Cancer Center, the Breast Oncology Center at the University of Michigan's Rogel Cancer Center and the Boca Raton Regional Hospital/Lynn Women's Health and Wellness Institute.

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials